

**Immune responses against recombinant poxvirus  
vaccines that express full-length lyssavirus glycoprotein  
genes**

by

Jacqueline Weyer

Submitted in partial fulfillment of the requirements for the degree of

**PHILOSOPHIAE DOCTOR  
(MICROBIOLOGY)**

in the

Department of Microbiology and Plant Pathology  
Faculty of Natural and Agricultural Sciences  
University of Pretoria  
Pretoria, South Africa

Supervisor: Professor Louis H. Nel

January 2006

I declare that the thesis, which I hereby submit for the degree Ph.D. at the University of Pretoria, Pretoria, is my own work and has not been submitted by me for a degree at another university

---

Jacqueline Weyer

## ACKNOWLEDGEMENTS

A simple “thank you” would not suffice; my deepest gratitude goes to you, the people that made a difference:

*From the University of Pretoria*

Professor Louis H. Nel

Wanda Markotter

Fellow students and friends in the Molecular Virology Laboratory

*From the Agricultural Research Council-Onderstepoort Veterinary Institute*

Professor Gerrit J. Viljoen (*formerly*)

Dr. Claude Sabeta

Janet Mans (*formerly*)

David B. Wallace

Colleagues and friends at the Applied Biotechnology Unit

*The Centers for Disease Control and Prevention*

Dr. Charles E. Rupprecht

Josh S. Self

Dr. Ivan Kuzmin

Michael Niezgodá

Trish Foster

Colleagues and friends at the Rabies Unit

*And my loving parents and family; Janine, Erik and Estian*

## SUMMARY

### **Immune responses against recombinant poxvirus vaccines that express full-length lyssavirus glycoprotein genes**

by

Jacqueline Weyer

Supervisor: Prof. Louis H. Nel  
Department of Microbiology and Plant Pathology  
University of Pretoria

For the degree PhD (Microbiology)

Rabies is a fatal but preventable neurotropic disease of potentially all mammals. The disease is caused by lyssaviruses. Rabies is recognized as the 10<sup>th</sup> most common lethal infectious disease in the world, rendering it one of the most feared zoonotic diseases known to man. Nevertheless, rabies can be prevented by application of pre- or post exposure treatments. Rabies vaccines have been available since the time of Pasteur, more than one hundred years ago. Since, vaccine research focused on the development of safer and more effective vaccines. Topics of current interest in the field of rabies vaccinology were addressed in this study. A primary concern regarding the disease is human mortalities, in the range of 60 000, reported every year. Most of these are linked to exposure to rabid dogs. In addition, a great number of post exposure treatments are administered each year at great costs. Despite availability of efficacious biologics, several factors influence the optimal use and accessibility of these agents in the countries of interest, with cost and availability being the major contributing factors.

A proven approach is mass oral vaccination of target animals, such as dogs, which indirectly infers protection to susceptible hosts, including man. Currently available vaccines present several disadvantages of use though, including issues of safety or

doubtful stability. Safer but effective alternative vaccines that could be used in oral baits would be valuable. Here the use of two candidate host restricted poxvirus vaccine vectors were explored, particularly also in regard to oral innocuity. The construction, convenient isolation and use of a recombinant Lumpy skin disease virus (Neethling strain) expressing rabies virus glycoprotein in a mouse model were investigated. In addition, a recombinant Modified Vaccinia virus Ankara expressing rabies virus glycoprotein was prepared and tested as a vaccine in mice, dogs and raccoons. In both cases it was clear that the severe attenuation of these viruses did affect the efficacy of the recombinant vaccines in the non-permissive hosts. With the recombinant MVA a clear dosage effect could be shown, and equivalent humoral responses could only be attained at much higher titers of vaccine virus as with replication competent counterparts.

Secondly, the cross-protection of rabies vaccines across the spectrum of lyssaviruses was addressed. Lyssaviruses can be divided into two groups based on sequence analysis and pathogenesis. Viruses belonging to the so-called phylogroup II, are the Mokola, Lagos and West Caucasian Bat viruses. Classic rabies biologics fail to fully protect against the viruses attributed to a lack of cross-neutralization. Here, cross-protection and cross-reactive immune responses induced by recombinant vaccinia viruses expressing rabies, Mokola or West Caucasian Bat virus glycoproteins, in single or dual combinations, were investigated. As expected, there was a lack of cross-protection of rabies and Mokola glycoprotein vaccines. There was also a clear lack of cross-protection of West Caucasian Bat virus glycoprotein vaccine and rabies and Mokola viruses. The dual antigen expressing vaccines did not appear to offer any additional protective effect in the tested model. The Mokola virus glycoprotein vaccines induced neutralizing antibody responses that significantly cross-neutralized Lagos Bat virus.

**TABLE OF CONTENTS**

<b>Acknowledgements</b>	<b>iii</b>
<b>Summary</b>	<b>iv</b>
<b>Table of contents</b>	<b>vi</b>
<b>List of abbreviations</b>	<b>xiv</b>
<b>List of figures</b>	<b>xvii</b>
<b>List of tables</b>	<b>xx</b>
<b><u>Part One: Introduction and literature review</u></b>	
<b>Chapter I: Introduction</b>	<b>2</b>
1.1 Background and motivation	2
1.2 Objectives of the study	3
1.3 Layout of the thesis	4
<b>Chapter II: Literature review</b>	<b>5</b>
2.1 Rabies – a topical overview	5
2.1.1 History of rabies: the development of prophylaxis and control strategies	5
2.1.2 Aetiology	9
2.1.2.1 Morphology and protein functions of the rabies virus	10
2.1.2.2 The glycoprotein	11
2.1.3 Immune responses against viruses	13
2.1.3.1 The immunogenicity of rabies virus proteins	14
2.1.3.2 Expression of rabies virus glycoprotein in different systems	16
2.1.4 The control and prevention of rabies	18
2.1.4.1 Transmission of rabies viruses	18
2.1.4.2 Control and prevention of urban rabies	19
2.1.4.3 Control and prevention of sylvatic rabies	20
2.1.4.4 Prevention in humans	21
2.1.5 Epidemiology of rabies viruses	23

2.1.6	Rabies in the developing world: rationale of control and elimination programs	24
2.2	Vaccines and vaccination – an overview	25
2.2.1	Concise account of the history of vaccinology	25
2.2.2	Types of vaccines	27
2.2.3	Poxviruses as vaccine carriers	27
2.2.3.1	Characteristics of the poxvirus group of viruses	27
2.2.3.2	Development of poxviruses as vaccine carriers	28
2.2.3.3	Modified Vaccinia virus Ankara	31
2.2.3.4	Lumpy Skin Disease virus vaccine strains	34

**Part Two: Preparation of recombinant Lumpy Skin Disease virus (Neethling strain) expressing a full-length rabies virus glycoprotein gene and evaluation of immunogenicity in a mouse model**

<b>Chapter III: Construction and isolation of recombinant lumpy skin disease virus (Neethling strain) expressing a full-length rabies virus glycoprotein gene</b>	<b>38</b>	
3.1	Introduction	38
3.2	Materials and methods	40
3.2.1	Recombinant plasmids and viruses	40
3.2.2	General cell culture procedures	41
3.2.2.1	Maintenance of cell culture	41
3.2.2.2	Preparation of primary fetal bovine testis cell culture	42
3.2.3	Generation of recombinant LSDV-SA: transfection of infected cell culture with recombinant transfer vector	43
3.2.4	Isolation of recombinant LSDV-SA: positive, dominant selection for mycophenolic acid selection	44
3.2.4.1	Classic plaque purification protocol	44
3.2.4.2	Filtration and sonication treatment of virus lysates supernatants to facilitate selection	45
3.2.4.3	Detergent treatment of recombinant LSDV-SA to facilitate selection of homogenous recombinant viruses	46

3.2.5	PCR analysis of the recombinant LSDV-SA	47
3.2.5.1	Nucleic acid extraction	47
3.2.5.2	Phenol/chloroform extractions and precipitation of genomic virus DNA	47
3.2.5.3	PCR analysis of homogeneity of recombinant LSDV-SA samples	48
3.2.5.4	PCR verification of integration of the expression cassette on the LSDV-SA genome	49
3.2.6	Analysis of stable expression of foreign genes from recombinant LSDV-SA: visualization of EGFP fluorescence and indirect immunofluorescence assay	50
3.2.7	Preparation of recombinant and parental virus for immunization of animals	51
3.2.7.1	Large scale growth of viruses from single foci isolates	51
3.2.7.2	Infectivity assay for LSDV-SA	52
3.3	Results	52
3.3.1	Generation of recombinant LSDV-SA	52
3.3.2	Selection of recombinant LSDV-SA	54
3.3.2.1	Classic plaque purification protocol	54
3.3.2.2	Filtration and sonication of virus lysates to facilitate selection	56
3.3.2.3	Detergent treatment of recombinant LSDV-SA to facilitate selection of homogenous recombinant viruses	57
3.3.3	Stable expression of foreign genes from recombinant LSDV-SA	58
3.4	Discussion	59
	<b>Chapter IV: Immune responses to recombinant Lumpy Skin Disease virus (Neethling strain) expressing a full-length rabies virus glycoprotein gene in a mouse model</b>	<b>63</b>
4.1	Introduction	63
4.2	Materials and methods	64
4.2.1	Viruses and animals	64
4.2.2	Immunization of animals	64
4.2.3	Rapid fluorescent focus inhibition test (RFFIT)	65
4.2.3.1	Preparation of the RFFIT	65
4.2.3.2	Fixation, staining and reading of the tests	66

4.2.4	Cytokine assay	66
4.3	Results	67
4.3.1	Rabies virus neutralizing responses to LSDV-RG	67
4.3.2	Cytokine responses to LSDV-RG	67
4.4	Discussion	69

**Part Three: Preparation of recombinant modified vaccinia virus Ankara and vaccinia virus Western Reserve strain expressing a full-length rabies virus glycoprotein gene and evaluation of immunogenicity in a mouse model**

**Chapter V: The construction and isolation of recombinant modified vaccinia virus Ankara and vaccinia virus Western Reserve strain expressing a full-length rabies virus glycoprotein gene** **73**

5.1	Introduction	73
5.2	Materials and methods	77
5.2.1	Viruses, plasmids and genes	77
5.2.2	General molecular biology and cell culture techniques	78
5.2.2.1	Molecular cloning techniques	78
5.2.2.2	Cell culture techniques	80
5.2.3	Molecular cloning of a full-length rabies virus glycoprotein gene and an EGFP gene in a MVA transfer vector	81
5.2.3.1	Construction of a MVA transfer vector, pIIIp7.5-JW	81
5.2.3.2	Subcloning of a rabies virus glycoprotein gene in a cloning vector, pMTL-24	84
5.2.3.3	Molecular cloning of the EGFP gene	85
5.2.3.4	Molecular cloning of the rabies virus glycoprotein and EGFP genes in pIII7.5-JW	85
5.2.4	Molecular cloning of a rabies virus glycoprotein gene in a vaccinia virus transfer vector, pGVWR1-gptNew	87
5.2.4.1	Modification of the vaccinia virus transfer vector, pGVWR1-gpt	87
5.2.4.2	Cloning of a rabies virus glycoprotein and EGFP genes in pGVWR1-gptNew	89

5.2.5	Analysis of transient expression of the rabies virus glycoprotein and EGFP genes in infected cell culture	89
5.2.5.1	Transfection with recombinant transfer vectors in infected cell culture	89
5.2.5.2	Visualization of EGFP fluorescence and indirect immunofluorescence analysis	90
5.2.6	Generation of recombinant vaccinia viruses: transfection of infected cell culture with recombinant transfer vector	91
5.2.7	Isolation of recombinant vaccinia viruses: positive, dominant selection for mycophenolic acid resistance	91
5.2.7.1	Analysis of homogeneity of recombinant vaccinia virus clones: PCR of the site of deletion III of the MVA genome and the TK region of the vaccinia virus Western Reserve strain genome	92
5.2.8	Analysis of stable expression of the rabies virus glycoprotein gene from recombinant vaccinia viruses: indirect immunofluorescence assay	94
5.2.9	Large scale growth and semi-purification of the parental and recombinant vaccinia viruses from single, plaque isolates	94
5.2.10	Infectivity assays	95
5.2.10.1	MVA immunostaining	95
5.2.10.2	Vaccinia virus Western Reserve and Copenhagen strains: plaque assay	96
5.2.11	Characterization of growth characteristics of the recombinant vaccinia viruses	97
5.2.11.1	MVA replication deficiency assay	97
5.2.11.2	One step growth assays	97
5.3	Results	98
5.3.1	Construction of a MVA transfer vector, pIIIp7.5-JW and molecular cloning and transient expression of rabies virus glycoprotein and EGFP genes	98
5.3.2	Construction of the vaccinia virus transfer vector, pGVWR1-gptNew	99
5.3.3	Generation and isolation of recombinant vaccinia viruses	100
5.3.4	Stable expression of rabies virus glycoprotein and EGFP genes from the recombinant MVA and vaccinia viruses	103
5.3.5	Growth characteristics of recombinant and parental vaccinia viruses	105
5.3.5.1	Replication deficiency assay for MVA	105
5.3.5.2	One step growth assays	105

5.3.6	Preparation of vaccine and parental virus for immunization of animals	106
5.4	Discussion	107
<b>Chapter VI: Immune responses to host-restricted and replication competent recombinant vaccinia viruses expressing full-length rabies virus glycoprotein genes</b>		<b>110</b>
6.1	Introduction	110
6.2	Materials and methods	111
6.2.1	Recombinant vaccine and challenge viruses and cell culture	111
6.2.2	Experimental animals	112
6.2.3	Preparation of challenge viruses	112
6.2.3.1	Preparation of suckling mouse brain homogenates	112
6.2.3.2	Titration of suckling mouse brain homogenates	113
6.2.3.3	Postmortem diagnosis of rabies infection in animals: Direct Fluorescent Antibody Test	113
6.2.4	Immunization studies in animals	114
6.2.4.1	Immunization of mice	114
6.2.4.2	Immunization of dogs and raccoons	117
6.3	Results	117
6.3.1	Preparation of challenge viruses	117
6.3.2	Survival and humoral responses in mice	118
6.3.3	Anamnestic responses in previously vaccinated dogs and raccoons	122
6.4	Discussion	123

**Part Four: Preparation of recombinant vaccinia virus expressing full-length Rabies and non-rabies lyssavirus glycoprotein genes and evaluation of immunogenicity and cross-protection in a mouse model**

<b>Chapter VII: Towards a cross-protecting lyssavirus vaccine: immune responses against recombinant vaccinia viruses expressing full-length lyssavirus glycoproteins</b>	<b>127</b>
7.1 Introduction	127
7.2 Materials and methods	131
7.2.1 Viruses, plasmids and genes	131
7.2.2 Animals used in the study	132
7.2.3 Molecular cloning of the WCBV glycoprotein gene	132
7.2.3.1 Polymerase chain reaction (PCR) of the WCBV glycoprotein gene and cloning in the PCR cloning vector, pGEM-T Easy®	132
7.2.3.2 Cloning of the WCBV glycoprotein gene in a vaccinia virus transfer vector, pGVWR-gptNew	134
7.2.4 Molecular cloning of a Mokola virus glycoprotein gene in pGVWR-gptNew	135
7.2.5 Generation and isolation of recombinant vaccinia viruses expressing lyssavirus glycoprotein genes	136
7.2.5.1 Purification of a recombinant vaccinia virus encoding a rabies virus glycoprotein gene	136
7.2.5.2 Transfection for the generation of recombinant vaccinia viruses	137
7.2.5.3 Purification and isolation of recombinant vaccinia viruses	138
7.2.5.4 Analysis of homogeneity of recombinant vaccinia virus clones: PCR of the site of HA and TK gene regions of the vaccinia virus Copenhagen genome	138
7.2.6 Expression analysis: indirect immunofluorescence analysis	140
7.2.6.1 Preparation of the vaccine viruses for immunization study	140
7.2.6.2 Large scale growth and semi-purification from single, plaque isolates	140
7.2.5.7 Titration	140
7.2.7 Preparation of WCBV challenge material	140
7.2.7.1 Amplification and preparation of WCBV suckling mouse brain homogenates	140
7.2.7.2 Titration of suckling mouse brain homogenates	141
7.2.8 Immunization and challenge study	141

7.2.9	Analysis of humoral responses: RFFIT	142
7.2.10	Statistical analysis of data	142
7.3	Results	143
7.3.1	Molecular cloning of WCBV glycoprotein gene in a vaccinia virus transfer vector	143
7.3.2	Molecular cloning of a Mokola virus glycoprotein gene in a vaccinia virus transfer vector	144
7.3.3	Generation of recombinant vaccinia viruses	145
7.3.4	Expression of lyssavirus glycoproteins from recombinant vaccinia viruses	147
7.3.5	Preparation of WCBV challenge material	150
7.3.6	Survival studies and humoral responses in mice	150
7.3.7	Cross-reactivity and cross-protection in mice	153
7.4	Discussion	154

## **Part Five: Discussion**

<b>Chapter VIII: Discussion</b>	<b>158</b>
<b>References</b>	<b>163</b>
Personal communications	196
Internet references	197
<b>Communications</b>	<b>198</b>
<b>Papers</b>	<b>199</b>
<b>Notes</b>	<b>200</b>

### LIST OF ABBREVIATIONS

A	Adenine
$A_{260}/A_{280}$	The ratio of absorption at 260nm and absorption at 280 nm
AD	<i>Anno Domini</i> of the Christian era/after Christ
ARC-OVI	Agricultural Research Council-Onderstepoort Veterinary Institute
AUG	Adenine Uracil Guanine (translation initiator codon)
BC	Before Christ
bp	Base pair
C	Cytosine
°C	Degrees Celsius
CDC	Centers for Disease Control and Prevention
CEC-32	Chicken embryo fibroblast cell line
CEF	Primary chick embryo fibroblasts
CO <sub>2</sub>	Carbon dioxide
CPE	Cytopathic effect
CTL	Cytolytic T lymphocyte
CVS	Challenge virus standard
DALY	Disability-adjusted life year
DMEM	Dulbecco's Modified Eagle's Medium
DMEM/F12	Dulbecco's Modified Eagle's Medium with Ham's F12 medium
DMSO	Dimethylsulfoxide
DNA	Deoxyribonucleic acid
<i>Ecogpt</i>	<i>Escherichia coli</i> guaninephosphoribosyltransferase
EBLV-1	European Bat Lyssavirus 1
EGFP	<i>Escherichia coli</i> green fluorescent protein
ERA	Evelyn-Rokitniki-Abelseth strain of rabies virus
FBT	Primary fetal bovine testis
FCS	Fetal calf serum
FITC	Fluorescein isothiocyanate
FFU	Focus forming units

$\gamma$	Gamma
G	Guanine
g	Gravitational force
Gs	Soluble glycoprotein
GFP	Green fluorescent protein
HA	Hemagglutinin
H <sub>2</sub> O	Water
HIV	Human Immunodeficiency Virus
IACUC	Institutional animal care and use committee
i.e	That is to say
IFN	Interferon
IL	Interleukin
Kb	Kilobasepair
KCL	Potassium chloride
KH <sub>2</sub> PO <sub>4</sub>	Potassium phosphate
KS-1	Kenya sheep-1 strain
LB	Luria Bertani
LSDV	Lumpy Skin DiseaseVirus
LSDV-RG	Recombinant Lumpy Skin Disease Virus (Neethling vaccine strain) expressing a full length rabies virus glycoprotein gene
LSDV-SA	Lumpy Skin Disease Virus Neethling vaccine strain
MEM	Minimum essential medium
MICLD <sub>50</sub>	Mouse intracranial lethal dose fifty
MOI	Multiplicity of infection
ml	Milliliter
mM	Millimolar
mRNA	Messenger ribonucleic acid
MPA	Mycophenolic acid
MVA	Modified Vaccinia Virus Ankara
n	Sample size
NaCL	Sodium chloride

Na <sub>2</sub> HPO <sub>4</sub> .2H <sub>2</sub> O	Hydrated sodium phosphate
nm	Nanometer
ORF	Open reading frame
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PEP	Post-exposure prophylaxis
PFU	Plaque forming units
PV	Pasteur Virus
P7.5K	Vaccinia virus early late promoter
P11K	Vaccinia virus late promoter
RFFIT	Rapid Fluorescent Focus Inhibition Test
RIG	Anti-rabies immunoglobulin
RG	Rabies virus glycoprotein
RNA	Ribonucleic acid
rpm	Rotations per minutes
s	Sedimentation coefficient
T	Thymine
TBE	Tris-Borate-Ethylenediaminetetraacetic acid buffer
TK	Thymidine Kinase
TKl	Thymidine Kinase gene left flanking region
TKr	Thymidine Kinase gene right flanking region
μ	Micro
U	Uracil
UGA	Uracil guanine adenine (translation termination codon)
USA	United States of America
UV	Ultraviolet
VNA <sub>b</sub>	Virus neutralizing antibody
V-RG	Vaccinia virus rabies glycoprotein recombinant vaccine
WCBV	West Caucasian Bat virus
WHO	World Health Organization
w/v	Weight per volume

## LIST OF FIGURES

**Chapter II**

Figure 2.1: The morphology of the rabies virion 10

Figure 2.2: Structure of the poxvirus virion 28

**Chapter III**

Figure 3.1: Circle map of the LSDV transfer vector, pLSEG, depicting the relevant features of the plasmid 41

Figure 3.2: A diagram depicting the binding position of the primers OP3 and RevG in the insertion region of the recombinant LSDV-SA genome 53

Figure 3.3: PCR verification of the integration of the expression cassette in the LSDV-SA genome 53

Figure 3.4: A diagrammatic representation of the regions and the sizes of the amplicons that can be expected with the OP3/OP49 primer pair 54

Figure 3.5: Electrophoretic profile of the representative results of the PCRs conducted on DNA templates prepared from recombinant LSDV-SA which was processed as described by Romero *et al.*, 1993 55

Figure 3.6: EGFP fluorescence recombinant LSDV-SA infected FBT cell culture 58

Figure 3.7: Indirect immunofluoresence analysis of rabies virus glycoprotein from LSDV-SA recombinants 59

**Chapter V**

Figure 5.1: The principles of transient marker stabilization 76

Figure 5.2: Plasmid map of MVA transfer vector, pIIIIdHRp7.5 82

Figure 5.3: Plasmid map of the cloning plasmid, pUC18 83

Figure 5.4: Plasmid map of the newly constructed MVA transfer vector, pIIIp7.5-JW 83

Figure 5.5:	A diagrammatic representation of the pUC-based cloning vector, pMTL24	84
Figure 5.6:	A plasmid map of the recombinant pFASTBac1-RabG plasmid	85
Figure 5.7:	Plasmid map of the recombinant pGEM-TEasy vector containing an EGFP gene	86
Figure 5.8:	Diagrammatic representation of the multiple cloning site of the pMTL-RabG recombinant plasmid	86
Figure 5.9:	A map of vaccinia transfer vectors	88
Figure 5.10:	Molecular cloning of the rabies glycoprotein and EGFP gene in the MVA transfer vector, pIIIp7.5-JW	99
Figure 5.11:	Cloning of a rabies glycoprotein and RGFP genes in pGVWR1-gptNew	100
Figure 5.12:	PCR amplification with primers binding in the flanking areas of the site of deletion III	102
Figure 5.13:	PCR amplification with primers binding in the flanking regions of the thymidine kinase locus	102
Figure 5.14:	Stable expression of EGFP in MVA-RG-EGFP and WR-RG-EGFP	103
Figure 5.15:	Indirect immunofluorescence assay of rabies glycoprotein in BHK-21 cell culture	104
Figure 5.16:	One step growth curves for recombinant and non-recombinant vaccinia viruses	106
<b>Chapter VI</b>		
Figure 6.1	Deaths of mice after challenge with rabies virus isolates	118
Figure 6.2	The survival of mice that receive vaccine constructs intramuscularly after lethal challenge with rabies virus	119
<b>Chapter VII</b>		
Figure 7.1:	Plasmid map of the PCR cloning vector, pGEM®-TEasy	134
Figure 7.2:	Plasmid map of the vaccinia transfer vector, pGVWR-gptNew	135

Figure 7.3:	PCR of the WCBV glycoprotein gene	143
Figure 7.4:	Electrophoretic profile of a pGVWR-WG clone with a gene in the correct orientation	144
Figure 7.5:	Molecular cloning of Mokola virus glycoprotein gene in the vaccinia transfer vector, pGVWR-gptNew	145
Figure 7.6:	PCR amplicons obtained with the VacTKl and VacTKr primers that anneal in the regions flanking the TK gene of the vaccinia virus Copenhagen genome	146
Figure 7.7:	PCR of the HA region of parent and recombinant vaccinia viruses	147
Figure 7.8:	Representative images of the results of the indirect immunofluorescence assays with the anti-rabies virus glycoprotein monoclonals	148
Figure 7.9:	Indirect immunofluorescence with anti-mokola glycoprotein monoclonal and polyclonal anti-WCBV serum	149
Figure 7.10:	Survivorship of mice vaccinated with recombinant vaccinia virus vaccines	150

## LIST OF TABLES

**Chapter II**

Table 2.1:	Expression of rabies virus glycoprotein genes in eukaryotic expression systems	17
------------	--	----

**Chapter III**

Table 3.1:	The nucleotide sequences and melting temperatures (T <sub>m</sub> ) values of the primer pair OP3 and OP49	49
Table 3.2:	The nucleotide sequences and melting temperatures (T <sub>m</sub> ) of the primers OP3 and RevG	50
Table 3.3:	The outcome of the PCR to determine homogeneity of different recombinant LSDV-SA samples prepared according to Romero <i>et al.</i> , 1993	55
Table 3.4:	The outcome of the PCR to determine homogeneity of different recombinant LSDV-SA samples treated by filtration	56
Table 3.5:	The outcome of the PCR to determine homogeneity of different recombinant LSDV-SA samples treated by sonication	56
Table 3.6:	The effect of detergent treatment on the isolation of homogenous isolates of recombinant LSDV-SA	56

**Chapter IV**

Table 4.1	Mouse IL-12 titers measured in pg/ml and n the number of serum samples tested per group	68
Table 4.2	Mouse IL-5 titers measured in pg/ml and n the number of serum samples tested per group	68
Table 4.3	Mouse IL-4 titers measured in pg/ml and n the number of serum samples tested per group	69
Table 4.4	Mouse IFN- $\gamma$ titers measured in pg/ml and n the number of serum samples tested per group	69

**Chapter V**

Table 5.1	Systems for selection of recombinant poxviruses	75
-----------	---	----

Table 5.2:	Cell cultures used in this study	80
Table 5.3:	Replication deficiency of recombinant MVA on non-permissive cell culture	105
Table 5.4	Titers of virus cultures obtained after a semi-purification procedure	107
<b>Chapter VI</b>		
Table 6.1:	Details of the schedule for the immunization of mice with recombinant vaccinia viruses	116
Table 6.2:	Serological responses of mice after intramuscular administration of the vaccine viruses	120
Table 6.3:	Serological responses of mice after oral administration of the vaccine viruses	121
Table 6.4:	Anamnestic responses in beagles after administration of the vaccine viruses	122
Table 6.5:	Anamnestic responses in beagles after administration of the vaccine viruses	122
<b>Chapter VII</b>		
Table 7.1:	Summary of available reports on the cross-protective efficacy and cross-reactivity of rabies commercial and experimental vaccines and immunoglobulins	129
Table 7.2:	Description of the recombinant vaccinia virus vaccines generated and tested in this study	137
Table 7.3:	Pre-challenge rabies virus neutralizing antibody titers and survivorship of mice vaccinated with recombinant vaccinia viruses and challenged with street rabies virus	152
Table 7.4:	Pre-challenge rabies virus neutralizing antibody titers and survivorship of mice vaccinated with recombinant vaccinia viruses and challenged with Mokola virus	152
Table 7.5:	Pre-challenge rabies virus neutralizing antibody titers and survivorship of mice vaccinated with recombinant vaccinia viruses and challenged with WCBV	153
Table 7.6:	Lagos Bat virus neutralizing antibody titers of mice vaccinated with recombinant vaccinia viruses	154